HYTRIN TABLET 1 mg

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

TERAZOSIN HCl

Available from:

ABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED

ATC code:

G04CA03

Dosage:

1 mg

Pharmaceutical form:

TABLET

Composition:

TERAZOSIN HCl 1 mg

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

Aesica Queenborough Limited

Authorization status:

ACTIVE

Authorization date:

2001-09-21

Patient Information leaflet

 
HYTRIN
®  
Terazosin Hydrochloride Tablets 

PRODUCT DESCRIPTION 
HYTRIN (terazosin hydrochloride), an alpha-1-selective adrenoceptor
blocking agent, is a 
quinazoline derivative represented by the following chemical name:
1-(4-amino-6,7-dimethoxy-2-
quinazolinyl)-4-[(tetrahydro-2-furanyl) carbonyl]-piperazine,
monohydrochloride, dehydrate. 

Terazosin hydrochloride occurs as a white, crystalline substance,
freely soluble in water and

isotonic saline and has a molecular weight of 459.93.
HYTRIN tablets for oral ingestion are 
supplied in four dosage strengths containing terazosin hydrochloride
dihydrate equivalent to 1 
mg, 2 mg, 5 mg and 10 mg terazosin. 

INDICATIONS 
Hytrin (terazosin hydrochloride) is indicated for the relief of
the manifestations of mild to moderate 
benign prostatic hyperplasia (BPH). Treatment should be stopped if
patients have not responded 
after three months of therapy.  

Terazosin is also indicated in the treatment of hypertension. It
can be used alone or in 
combination with other antihypertensive agents such as diuretics
or beta-adrenergic blocking 
agents. 

DOSAGE AND ADMINISTRATION 
The dose of terazosin should be adjusted according to the patient's
individual response. The 
following is a guide to its administration: 

Initial Dose: 1 mg at bedtime is the starting dose for all patients,
and this dose should not be 
exceeded. This initial dosing regimen should be strictly
observed to minimize the potential for 
severe hypotensive effects. 

_Subsequent Doses:  _
BENIGN PROSTATIC HYPERPLASIA (BPH): 
The dose may be slowly increased to achieve
the desired clinical response in BPH patients. The 
usual recommended dose range is 5 to10 mg administered once a
day. Treatment should 
commence with one tablet of 1 mg taken at bedtime for the first
4 days, then every morning for 
the next 3 days. For the next seven days, the dosage is one
tablet of 2 mg every morning. In the 

Summary of Product characteristics

HYTRIN
®
Terazosin Hydrochloride Tablets
PRODUCT DESCRIPTION
HYTRIN
(terazosin
hydrochloride),
an
alpha-1-selective
adrenoceptor
blocking
agent,
is
a
quinazoline derivative represented by the following chemical name:
1-(4-amino-6,7-dimethoxy-2-
quinazolinyl)-4-[(tetrahydro-2-furanyl) carbonyl]-piperazine,
monohydrochloride, dehydrate.
Terazosin hydrochloride occurs as a white, crystalline substance,
freely soluble in water and
isotonic saline and has a molecular weight of 459.93. HYTRIN tablets
for oral ingestion are
supplied in four dosage strengths containing terazosin hydrochloride
dihydrate equivalent to 1
mg, 2 mg, 5 mg and 10 mg terazosin.
INDICATIONS
Hytrin (terazosin hydrochloride) is indicated for the relief of the
manifestations of mild to moderate
benign prostatic hyperplasia (BPH). Treatment should be stopped if
patients have not responded
after three months of therapy.
Terazosin is also indicated in the treatment of hypertension. It can
be used alone or in
combination with other antihypertensive agents such as diuretics or
beta-adrenergic blocking
agents.
DOSAGE AND ADMINISTRATION
The dose of terazosin should be adjusted according to the patient's
individual response. The
following is a guide to its administration:
Initial Dose: 1 mg at bedtime is the starting dose for all patients,
and this dose should not be
exceeded. This initial dosing regimen should be strictly observed to
minimize the potential for
severe hypotensive effects.
_Subsequent Doses: _
BENIGN PROSTATIC HYPERPLASIA (BPH):
The dose may be slowly increased to achieve the desired clinical
response in BPH patients. The
usual recommended dose range is 5 to10 mg administered once a day.
Treatment should
commence with one tablet of 1 mg taken at bedtime for the first 4
days, then every morning for
the next 3 days. For the next seven days, the dosage is one tablet of
2 mg every morning. In the
third week, the dosage is increased to one tablet of 5 mg every
morning. As from the fourth week,
a maintenance dosage of 5-10 mg is taken daily each